Kymab Announces Promising Results from Initial Clinical Study of New Antibody KY1005 for Treatment of Autoimmune Diseases

  • Top-line Phase I data demonstrated favorable safety, pharmacokinetics and pharmacodynamic properties that support advancement of KY1005 into patient Phase 2 studies
  • KY1005, a fully human monoclonal antibody, is an antagonist of OX40-Ligand (OX40L) with the potential to treat a number of immune mediated and inflammatory disorders (autoimmune diseases)
  • The study demonstrated an early proof of mechanism of action, as KY1005 was seen to block T-cell-driven inflammation in the skin

Cambridge, UK; 30 July 2018: Kymab, a clinical-stage biopharmaceutical company developing fully human monoclonal antibody therapeutics, announces today that it has obtained positive data in its Phase I trial of KY1005 and will proceed to Phase II studies in atopic dermatitis, with additional plans to run studies in other immune-mediated diseases, such as Graft-versus-Host Disease (GvHD).